Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a
single, acquired genetic abnormality. Identification of the BCR-ABL kinase fusion protein …

Acquired blood eosinophilia is considered either a primary or a secondary phenomenon.
Causes of secondary (ie, reactive) eosinophilia include tissue-invasive parasitosis, allergic …

Self‐renewal of Bcr‐Abl+ chronic myeloid leukemia (CML) cells is sustained by a nuclear
activated serine/threonine‐(S/T) unphosphorylated β‐catenin. Although β‐catenin can be …

The constitutively activated Abl tyrosine kinase domain of the chimeric Bcr-Abl oncoprotein
is responsible for the transformation of haematopoietic stem cells and the symptoms of …

The targeted inactivation of oncogenes offers a rational therapeutic approach for the
treatment of cancer. However, the therapeutic inactivation of a single oncogene has been …

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic
mutations. Such agents can have remarkable activity against some cancers, although …

Updated findings from a randomised comparison of imatinib versus previous standard
treatment in the treatment of newly diagnosed chronic myeloid leukaemia suggest that this …

The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid
leukemia (CML) and is the standard front-line therapy for patients in chronic phase …

A6 IK3I/506 30 6 8: The invention provides methods and compositions for treat A6
IK3I/52(2006.015 ing conditions mediated by various kinases wherein Substi A6 …

In many cancers, somatic mutations confer tumorigenesis and drug-resistance. The recently
established clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 …